Abstract
The discovery of hepatocyte growth factor (HGF) in the early 1980s was followed by years of research into its role as an essential factor for normal human growth and development as well as its putative role in neoplasia signaling. The recognition that HGF and its tyrosine kinase receptor, mesenchymal-epithelial transition (MET) factor, constitute an essential signaling pathway in many cancers led to the development of corresponding targeted therapies. The signaling mediated by the HGF/c-Met system mediates crucial downstream effects in gliomas and is therefore considered a highly important target in these tumors. This review examines the research into the HGF/c-Met pathway in cancer with a focus on gliomas.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
